RecruitingNCT03717844

Registry for Adults With Plasma Cell Disorders (PCD's)

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment

2,000 participants

Start Date

Feb 9, 2018

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma Amyloidosis Smoldering Multiple Myeloma Plasma Cell Leukemia Cryoglobulinemia Castleman's Disease Light Chain Deposition Disease Heavy Chain Deposition Disease Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes

Summary

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry is collecting health information and tracking outcomes over time for adults with plasma cell disorders — a group of blood conditions involving abnormal growth of plasma cells — including conditions ranging from a pre-cancer state (MGUS) to active multiple myeloma, to improve understanding and care for these conditions. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a plasma cell disorder, including MGUS, smoldering myeloma, multiple myeloma, amyloidosis, POEMS syndrome, or related conditions - You are receiving care at UNC Cancer Hospitals or an affiliated clinic - You can read and speak English **You may NOT be eligible if...** - You have a physical or psychiatric condition that your doctor believes would prevent you from participating Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.